On Oct 18, major Wall Street analysts update their ratings for $Intuitive Surgical (ISRG.US)$, with price targets ranging from $525 to $555.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $416 to $549.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Stifel analyst Rick Wise maintains with a buy rating, and adjusts the target price from $475 to $525.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $518 to $535.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and adjusts the target price from $525 to $555.
Furthermore, according to the comprehensive report, the opinions of $Intuitive Surgical (ISRG.US)$'s main analysts recently are as follows:
The expectation of a significant revenue outperformance for FY25 appears to be a prevailing sentiment. This perspective is reinforced by the company's recent quarterly report, which prompted a revision of the estimated earnings per share for FY25, increasing it approximately by 3%.
Intuitive Surgical registered 'strong' results for Q3, particularly excelling in the two most vital metrics—DV5 placements and procedure growth. Seven months post the U.S. approval of da Vinci 5, Intuitive Surgical is experiencing significant post-launch growth momentum. The early adoption of DV5 is surpassing the initial uptake of the fourth-generation system, indicating a promising potential for accelerated growth as we look towards 2025.
The company's Q3 earnings and revenue exceeded expectations, accompanied by a procedure volume growth of 18% which also surpassed the consensus by 100bps. With a series of regulatory approvals for Dv5, it is anticipated that the growth momentum of Dv5 will be maintained, even as it enters into a wider release in the second half of FY25.
The conviction in the sustained upward potential of Intuitive Surgical strengthens, supporting its premium valuation. It stands out as a top-tier long-term growth prospect following the company's performance that surpassed estimates and showcased accelerated growth across various metrics.
Here are the latest investment ratings and price targets for $Intuitive Surgical (ISRG.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月18日，多家華爾街大行更新了$直覺外科公司 (ISRG.US)$的評級，目標價介於525美元至555美元。
富國集團分析師Larry Biegelsen維持買入評級，並將目標價從416美元上調至549美元。
奧本海默控股分析師Suraj Kalia維持持有評級。
斯迪富分析師Rick Wise維持買入評級，並將目標價從475美元上調至525美元。
BTIG分析師Ryan Zimmerman維持買入評級，並將目標價從518美元上調至535美元。
加皇資本市場分析師Shagun Singh Chadha維持買入評級，並將目標價從525美元上調至555美元。
此外，綜合報道，$直覺外科公司 (ISRG.US)$近期主要分析師觀點如下：
對於FY25有顯著營業收入超出預期的期望似乎是一種主流情緒。這一觀點得到了公司最近季度報告的支持，該報告促使對FY25預計每股收益的修訂，將其增加了約3%。
直覺外科在Q3獲得"強勁"的業績，特別是在兩個最關鍵的度量標準——DV5設備安置和程序成長方面表現出色。在美國批准達芬奇5七個月後，直覺外科正經歷着顯著的發售後增長動力。DV5的早期採用正在超越第四代系統的初期接受水平，這表明在展望2025年時存在加速增長的潛力。
公司Q3的收入和營業收入均超出預期，並伴隨着18%的程序成交量增長，也超過了共識預期的100個點子。隨着Dv5獲得一系列監管批准，預計Dv5的增長勢頭將得到保持，即使在FY25下半年進入更廣泛的市場時也是如此。
對直覺外科持續上升潛力的信念加強了，這支持了其溢價估值。在公司的表現超出預期並展示了各種指標加速增長之後，它成爲了一個頂級的長期增長前景。
以下爲今日7位分析師對$直覺外科公司 (ISRG.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
